Search results
Results from the WOW.Com Content Network
Chloroquine is an antiparasitic medication that treats malaria. It works by increasing the levels of haeme in the blood, a substance toxic to the malarial parasite. This kills the parasite and stops the infection from spreading. [1]
Doses given are appropriate for adults and children aged 12 and over. Other chemoprophylactic regimens that have been used on occasion: Dapsone 100 mg and pyrimethamine 12.5 mg once weekly (available as a combination tablet called Maloprim or Deltaprim): this combination is not routinely recommended because of the risk of agranulocytosis;
Children and adults should receive 25 mg of chloroquine per kg given over three days. A pharmacokinetically superior regime, recommended by the WHO, involves giving an initial dose of 10 mg/kg followed 6–8 hours later by 5 mg/kg, then 5 mg/kg on the following two days.
The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl: 10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
[3] [4] Although all risk cannot be excluded, it remains a treatment for rheumatic disease during pregnancy. [5] Hydroxychloroquine is in the antimalarial and 4-aminoquinoline families of medication. [3] Hydroxychloroquine was approved for medical use in the United States in 1955. [3] It is on the World Health Organization's List of Essential ...
Critics have long argued that while studying the effects of Red Dye No. 3 in humans poses ethical and scientific challenges, its ban in cosmetics should have logically extended to the food supply.
For premium support please call: 800-290-4726 more ways to reach us more ways to reach us
On 1 April 2020, the European Medicines Agency (EMA) issued guidance that chloroquine and hydroxychloroquine are only to be used in clinical trials or emergency use programs. [43] On 9 April 2020, the National Institutes of Health began the first clinical trial to assess whether hydroxychloroquine is safe and effective to treat COVID-19.